GORE RECEIVES FDA APPROVAL FOR BREAKTHROUGH ENDOVASCULAR DEVICE IN COMPLEX AORTIC ANEURYSMS

First off-the-shelf solution for treatment of complex aneurysmal disease involving the visceral aorta.

Jan 25, 2024

GORE ANNOUNCES FIRST PATIENT IMPLANT IN THE ARISE II PIVOTAL STUDY OF THE GORE<sup>®</sup> ASCENDING STENT GRAFT

CAUTION: Investigational device. Limited by United States law to investigational use.

Dec 20, 2023

THE GORE RELIEF CLINICAL STUDY BEGINS RANDOMIZING PATIENTS TO EVALUATE PFO CLOSURE FOR MIGRAINE HEADACHE RELIEF

CAUTION: Investigational device. Limited by United States law to investigational use.

Oct 15, 2023

GORE ANNOUNCES FIRST U.S. ENROLLMENT FOR THE GORE® VIAFORT VASCULAR STENT ILIOFEMORAL STUDY

CAUTION: Investigational device. Limited by United States law to investigational use.

Jun 6, 2023

GORE ANNOUNCES FIRST U.S. ENROLLMENT FOR THE GORE<sup>®</sup> VIAFORT VASCULAR STENT IVC STUDY

CAUTION: Investigational device. Limited by United States law to investigational use.

Mar 28, 2023

GORE INITIATES THE RELIEF CLINICAL STUDY EVALUATING PFO CLOSURE FOR MIGRAINE HEADACHE RELIEF

CAUTION: Investigational device. Limited by United States law to investigational use.

Nov 1, 2022

Gore Completes First In-human Implants of the GORE® VIAFORT Vascular Stent

CAUTION: Investigational device. Limited by United States law to investigational use.W. L. Gore & Associates initiates its GORE® VIAFORT Device Pivotal Clinical Study for the treatment of inferior

Oct 28, 2022